protein degradation

Roche pays $50M upfront to Monte Rosa in molecular glue deal
Roche pays $50M upfront to Monte Rosa in molecular glue deal
Fierce Biotech
Roche
molecular glue
Monte Rosa
QuEEN
protein degradation
Flag link:
Nurix and Seagen Collaborate on Breakthrough Cancer Therapeutics
Nurix and Seagen Collaborate on Breakthrough Cancer Therapeutics
Globe Newswire
Nurix Therapeutics
Seagen
protein degradation
cancer
antibody-drug conjugate
Flag link:
Astellas notches another protein degrader pact with $21M upfront for PeptiDream
Astellas notches another protein degrader pact with $21M upfront for PeptiDream
Fierce Biotech
Astellas
protein degradation
PeptiDream
Flag link:
Astellas delves deeper into protein degrading drugs with Cullgen deal
Astellas delves deeper into protein degrading drugs with Cullgen deal
BioPharma Dive
Astellas
Cullgen
protein degradation
Flag link:
Proxygen, averaging a new collab every 10 months, sticks $2.5B molecular glue deal with Merck
Proxygen, averaging a new collab every 10 months, sticks $2.5B molecular glue deal with Merck
Fierce Biotech
Merck
Proxygen
molecular glue
protein degradation
Flag link:
At EpiBiologics, a pair of Genentech alumni wants to make next-gen protein degraders
At EpiBiologics, a pair of Genentech alumni wants to make next-gen protein degraders
BioPharma Dive
Genentech
EpiBiologics
protein degradation
Flag link:
First Protein Degrader Tested Outside Oncology Yields Promising Results
First Protein Degrader Tested Outside Oncology Yields Promising Results
BioSpace
Kymera Therapeutics
Sanofi
protein degradation
hidradenitis suppurativa
atopic dermatitis
KT-474
Flag link:
Pfizer's $1B protein degradation bet yields 3% response rate in Arvinas' midphase breast cancer trial
Pfizer's $1B protein degradation bet yields 3% response rate in Arvinas' midphase breast cancer trial
Fierce Biotech
Pfizer
protein degradation
Arvinas
clinical trials
breast cancer
ARV-471
Flag link:
Merck KGaA Strikes $550M Deal with Proxygen in Latest Protein Degradation Deal
Merck KGaA Strikes $550M Deal with Proxygen in Latest Protein Degradation Deal
BioSpace
Merck KGaA
Proxygen
protein degradation
Flag link:
Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation
Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation
Yahoo/Accesswire
Evotec
Bristol Myers Squibb
protein degradation
Flag link:
Plexium nabs $102M for protein degradation work weeks after $500M Amgen tie-up
Plexium nabs $102M for protein degradation work weeks after $500M Amgen tie-up
Fierce Biotech
Plexium
Amgen
protein degradation
venture capital
funding
Flag link:
Origami Therapeutics developing treatments for neurodegenerative diseases with ML and computational chemistry
Origami Therapeutics developing treatments for neurodegenerative diseases with ML and computational chemistry
MedCity News
Origami Therapeutics
protein degradation
neurodegenerative disease
Huntington's disease
Flag link:
Novartis makes protein degrader play, inking deal with new British startup to access fruits of novel tech
Novartis makes protein degrader play, inking deal with new British startup to access fruits of novel tech
Fierce Biotech
Novartis
protein degradation
Dunad Therapeutics
biobucks
Flag link:
Lilly-backed Lycia Therapeutics nabs $70M round for its protein degradation tech
Lilly-backed Lycia Therapeutics nabs $70M round for its protein degradation tech
Fierce Biotech
Lycia Therapeutics
protein degradation
Eli Lilly
funding
Flag link:
Eli Lilly To Utilize Lycia's LYTAC Platform To Treat Challenging Disease Areas
Eli Lilly To Utilize Lycia's LYTAC Platform To Treat Challenging Disease Areas
NASDAQ
Eli Lilly
Lycia Therapeutics
R&D
drug development
protein degradation
LYTACs
Flag link:
Pfizer funnels $1B into protein degrader Arvinas, with more in biobucks on the table
Pfizer funnels $1B into protein degrader Arvinas, with more in biobucks on the table
Fierce Biotech
Pfizer
Arvinas
breast cancer
protein degradation
biobucks
Flag link:
Eli Lilly, Novartis back a biotech startup boasting 'best of both worlds' protein degraders
Eli Lilly, Novartis back a biotech startup boasting 'best of both worlds' protein degraders
Endpoints
Eli Lilly
Novartis
protein degradation
Amphista
Flag link:
Lilly backs a biotech's spinout and places a small bet on protein degradation
Lilly backs a biotech's spinout and places a small bet on protein degradation
BioPharma Dive
Eli Lilly
Seed Therapeutics
protein degradation
Flag link:
Monte Rosa raises $96M Series B for drug development platform technology
Monte Rosa raises $96M Series B for drug development platform technology
MedCity News
Monte Rosa
drug development
protein degradation
Flag link:
Kymera Therapeutics, fresh off a $2B Sanofi biobucks pact, guns for an IPO
Kymera Therapeutics, fresh off a $2B Sanofi biobucks pact, guns for an IPO
Fierce Biotech
Kymera Therapeutics
IPOs
Sanofi
protein degradation
Flag link:

Pages